Investors, creating value for our company, our shareholders and society

Upcoming events

25Jul

2024

Second quarter 2024 results

Second quarter 2024 results will be reviewed by management during a live audio webcast with the financial community on July 25^th, 2024. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EST)

Quarterly Results

Discover more

25Oct

2024

Third quarter 2024 results

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community on October 25^th, 2024. The presentation will be followed by a Q&A session.

14:00 - 15:30 CET (8:00am – 9:30am EST)

Quarterly Results

Discover more

All our events

Press releases

June 28, 2024

Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS

Read the Press Release

June 26, 2024

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

Read the Press Release

June 25, 2024

Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

Read the Press Release

See more press releases

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.